Precision medicine of methotrexate in the patients with rheumatoid arthritis

Precision medicine of methotrexate in the patients with rheumatoid arthritis - Methotrexate precision medicine

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027250

Enrollment

Registered

2017-05-08

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

MTX administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In patient with rheumatoid arthritis and/or osteoarthritis, they have scheduled surgery of total Hip Arthroplasty (THA) and/or total Knee Arthroplasty (TKA) and administered MTX or no administration of MTX

Exclusion criteria

Exclusion criteria: Patients including infectious disease (Hepatitis B, C, HIV, syphilis) ministration of MTX

Design outcomes

Primary

Measure	Time frame
MTX therapeutic response and adverse drug reaction	—

Countries

Japan

Contacts

Public ContactMasayuki Hashiguchi

Keio University Faculty of Pharmacy

hashiguchi-ms@pha.keio.ac.jp03-5400-2120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026